Sunesis Pharmaceuticals - Inspired to Make a Difference in Cancer Patients Lives.


NASDAQ | SNSS (Common Stock) $2.74 -0.2
Stock chart for: SNSS.O.  Currently trading at $2.74 with a 52 week high of $6.30 and a 52 week low of $2.73.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Our most advanced program is QINPREZO™ (vosaroxin), our product candidate for the potential treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative, or AQD—a class of compounds that has not been used previously for the treatment of cancer. Sunesis has built a highly experienced cancer drug development organization committed to advancing vosaroxin in multiple indications to improve the lives of people with cancer.
More »